Immune recovery following antineoplastic chemotherapy and highly active antiretroviral therapy (HAART) in a child with HIV-1 infection previously unresponsive to HAART.
We report the case of a perinatally HIV-1-infected child, previously immunologically unresponsive to antiretroviral treatments (including the highly active antiretroviral therapy), who instead developed a vigorous and long-lasting immune response after the highly active antiretroviral therapy was associated with antineoplastic chemotherapy undertaken for a B-cell non-Hodgkin bone lymphoma.
Galli
L
L
Division of Paediatric Infectious Diseases, University of Florence, Anna Meyer Children's Hospital, Florence, Italy.
Chiappini
E
E
Lippi
A
A
de Martino
M
M
D000293:Adolescent; D015703:Antigens, CD / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D016130:Immunophenotyping; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D019562:Viral Load
D015703:Antigens, CD; D000970:Antineoplastic Agents